i-Base home
Search Menu
  • Home
  • HTB
  • 2019
  • March
  • 28

HTB

28 March 2019

Contents

Editorial

  • 29 March 2019: vol 20 no 4 – second CROI reports

Conference reports

  • Conference on Retroviruses and Opportunistic Infections (CROI 2019): second reports
  • Maturation inhibitor GSK’232 reduces viral load by –1.5 log at day 10
  • Capsid inhibitor GS-6207 shows potential for 3-monthly injections
  • First phase 1 results from bNAb PGT121 in HIV positive people
  • Dolutegravir/3TC dual ART is as effective at lowest viral load cut-off as triple therapy in GEMINI studies
  • Same-day ART is effective in San Francisco Rapid-ART clinic
  • Integrase inhibitors and neural tube defects: more data still needed
  • Double-dose levonorgestrel implant does not overcome interaction with efavirenz
  • Efavirenz and rifampicin together reduce levels of injectable contraception
  • Bedaquiline and delamanid safe when given together to treat drug resistant TB
  • Isoniazid preventative therapy in HIV positive pregnant women not linked to poor outcomes

Pregnancy

  • Dear Doctor letter: Increased risk of treatment failure and increased risk of mother-to-child transmission of HIV infection dues to lower exposure of elvitegravir and cobicistat during the second and third trimesters of pregnancy

PDFs

  • 29 March 2019 vol 20 no 4
  • HTB RSS

Early access

  • Promising data for multipurpose technologies to prevent HIV and pregnancy 24 February 2021
  • Community murals in Soweto on dolutegravir-based ART: an i-Base collaboration 22 February 2021
  • Timothy Ray Brown: a virtual memorial 21 February 2021
  • Main COVID-19 variants and their likely impacts on vaccines 16 February 2021
  • All early access reports

Current issues

  • February 2021
  • January 2021
  • December 2020
  • Back issues

Special report

  • Early results report 90% efficacy with from Pfizer/BioNTech COVID vaccine 11 November 2020

More from HTB

  • Conference reports
  • Conference shortcuts
  • Articles by subject
  • PDFs
  • Subscribe
  • HTB homepage

Home

  • i-Base homepage

This website sets no cookies from us or anyone else.

Information on this website is provided by treatment advocates and offered as a guide only. Decisions about your treatment should always be taken in consultation with your doctor.

This site complies with the HONcode standard for trustworthy health information.

Verify here.

HIV i-BASE
About us - Contact - Cookies and privacy - Copyright waiver - Terms of use - Home
107 The Maltings, 169 Tower Bridge Road, London SE1 3LJ.
Tel + 44 (0) 208 616 2210. Email admin@i-base.org.uk
Registered charity no: 1081905. Company reg no: 3962064.

Search i-Base

Site navigation

Quick links
HIV positive
Advocate
Professional
Donate
Feedback
Advice and information
Q and A
Phoneline
Pocket info
Guides
HIV meds
Glossary
Research and conference reports
HTB
HTB South
Pipeline report
Publications and resources
Publications
Other resources
Translations
Slide sets
Order and subscribe
News and updates
News
Blogs
Advocates' network
UK-CAB
Training manual
i-Base
About us
Contact
Sitemap
Home
Find us on Facebook